Tesamorelin
A synthetic analogue of GHRH with a trans-3-hexenoic acid group conjugated to the N-terminus, improving stability against DPP-IV degradation. Tesamorelin has been extensively studied for visceral adiposity reduction and GH axis stimulation with a favorable safety profile compared to direct GH administration.
Research Use Only. Tesamorelin is sold exclusively for in vitro research and laboratory use by qualified scientists. Not for human consumption, veterinary use, or clinical administration.
Research Literature
Published Research
Tesamorelin is a stabilized GHRH analogue with DPP-IV resistance, extensively studied for visceral adiposity reduction and GH axis modulation.
Tesamorelin reduces visceral adiposity in HIV-associated lipodystrophy
Key finding: Phase III trial demonstrated significant visceral fat reduction vs placebo over 26 weeks.
PubMed 19095984 ↗GH and IGF-1 modulation by tesamorelin
Key finding: Tesamorelin consistently elevated IGF-1 into normal range while preserving physiological GH pulsatility.
PubMed 20566952 ↗Tesamorelin cardiovascular and metabolic effects
Key finding: Metabolic improvements including reduced triglycerides and improved insulin sensitivity documented alongside fat reduction.
PubMed 22551580 ↗Same Category